OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colon Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms OMICC
- 12 Aug 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2021.
- 12 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2018 to 1 Oct 2019.
- 29 Nov 2018 Status changed from not yet recruiting to recruiting.